logo
The Nasdaq Just Entered a New Bull Market. Is It Too Late to Buy the Invesco QQQ ETF?

The Nasdaq Just Entered a New Bull Market. Is It Too Late to Buy the Invesco QQQ ETF?

Globe and Mail14-07-2025
Key Points
The tech-heavy Nasdaq-100 index plunged into a bear market in April, after President Trump announced his "Liberation Day" tariffs.
The index has since recovered and recently set a fresh record high, so a new bull market has officially begun.
The Invesco QQQ Trust tracks the performance of the Nasdaq-100, and its stellar track record suggests it's not too late for long-term investors to buy.
10 stocks we like better than Invesco QQQ Trust ›
The Nasdaq-100 is home to 100 of the largest non-financial companies listed on the Nasdaq stock exchange. It's typically used as a yardstick for the performance of the technology industry because some of its top holdings include powerhouses like Nvidia, Microsoft, and Apple.
The Nasdaq-100 plunged into bear market territory in April after losing 23% of its peak value, driven by President Donald Trump's "Liberation Day" tariffs, which threatened to derail the global economy. But most of America's trading partners are now at the negotiating table, so the president placed his most aggressive import penalties on hold. As a result, the index has recovered and is now trading at a new record high, which means a fresh bull market is underway.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
The Invesco QQQ Trust (NASDAQ: QQQ) is an exchange-traded fund (ETF) that tracks the performance of the Nasdaq-100, so it offers a simple way for investors to own a slice of the entire index. Did investors miss their opportunity to buy the dip earlier this year, or is more upside on the way? Read on.
The "Magnificent Seven" pulled the Nasdaq out of its slump
The " Magnificent Seven" is a group of companies that lead different segments of the technology industry. They earned the name for their incredible size and their ability to consistently outperform the rest of the stock market. The seven companies represent an eye-popping 42.1% of the Nasdaq-100 index and, by extension, the Invesco QQQ ETF:
Stock
Invesco ETF Portfolio Weighting
Nvidia
9.12%
Microsoft
8.68%
Apple
7.55%
Amazon
5.55%
Alphabet
4.80%
Meta Platforms
3.68%
Tesla
2.73%
Data source: Invesco. Portfolio weightings are accurate as of July 2, 2025, and are subject to change.
The Nasdaq-100 set its bear-market bottom on April 8, and it has since climbed by almost 34%. But the Magnificent Seven stocks have delivered average and median returns of 35% over the same period.
Data by YCharts.
Nvidia and Microsoft are the only two stocks in the Magnificent Seven to set a new record high since April, so the group might still have room for upside from here. Most of the seven companies also have solid fundamentals that support further gains, mainly because they are leaders in different areas of the artificial intelligence (AI) race.
Nvidia supplies graphics processing units (GPUs) for data centers, which are the most powerful chips for developing AI. Microsoft, on the other hand, is successfully commercializing an advanced AI assistant called Copilot, and the company also offers a growing portfolio of AI services through its Azure cloud platform.
Amazon and Alphabet are Microsoft's biggest competitors in the AI cloud space, and they have each developed their own AI assistants, too. Then there is Meta Platforms, which created the Llama open-source large language models (LLMs), in addition to its own chatbot called Meta AI.
But the Invesco ETF is home to several other prominent AI companies outside of the Magnificent Seven. In the semiconductor space, there are Broadcom, Advanced Micro Devices, and Micron Technology. Then on the AI software side, the ETF holds Palantir Technologies, Palo Alto Networks, CrowdStrike, Atlassian, and Datadog.
This could be a great time to buy the Invesco QQQ ETF
The Nasdaq-100 has experienced seven bear markets since the Invesco QQQ ETF was established in 1999. Nevertheless, the ETF has still delivered a compound annual return of 10.1% over the last 26 years, which highlights the benefits of taking a long-term approach and holding through volatility.
The ETF has also generated an accelerated annual return of 18.7% over the last 10 years, thanks to the proliferation of technologies like smartphones, advanced semiconductors, cloud computing, enterprise software, and now, AI. It's difficult to predict which companies will unlock the most value from AI over the long run because the industry is moving so fast, having spawned several trillion-dollar opportunities already.
In 2023, Bloomberg estimated that generative AI would become a $1.3 trillion industry by 2032. But in May of this year, Salesforce CEO Mark Benioff predicted agentic AI -- which wasn't even a mainstream concept until a few months ago -- could become a $12 trillion market on its own. In the hardware space, Nvidia CEO Jensen Huang thinks data center operators will be spending $1 trillion per year to build AI infrastructure by 2028.
Investors who buy the Invesco QQQ ETF won't have to separate the winners from the losers, because they will own a slice of the biggest players in each segment of the AI industry. This will probably be a very effective strategy, so even though the ETF just set a new record high, it's likely still a great buy for anyone willing to hold onto it for the next five to 10 years (or more).
Should you invest $1,000 in Invesco QQQ Trust right now?
Before you buy stock in Invesco QQQ Trust, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!*
Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 7, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, Apple, Atlassian, CrowdStrike, Datadog, Meta Platforms, Microsoft, Nvidia, Palantir Technologies, Salesforce, and Tesla. The Motley Fool recommends Broadcom, Nasdaq, and Palo Alto Networks and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

3 Unstoppable Stocks to Buy in August
3 Unstoppable Stocks to Buy in August

Globe and Mail

time16 minutes ago

  • Globe and Mail

3 Unstoppable Stocks to Buy in August

Key Points Investors have multiple reasons to like AbbVie stock. Eli Lilly remains a top stock to buy and hold. Vertex Pharmaceuticals is moving quickly to expand its markets beyond cystic fibrosis. 10 stocks we like better than AbbVie › The "it" factor. Some stocks have it. Other stocks don't. But the ones that do can be virtually unstoppable. Three Motley Fool contributors believe they've found such unstoppable stocks with the "it" factor to buy in August -- and they're all in the healthcare sector. Here's why they picked AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). There are many reasons to buy this stock Prosper Junior Bakiny (AbbVie): It's been a little over two years since AbbVie lost patent exclusivity for its best-selling drug, autoimmune disease medicine Humira. That didn't stop AbbVie, though; it just slowed it down momentarily. The company rebounded nicely and has since returned to top-line growth. AbbVie now owns another one of the top-10 selling therapies in the world, Skyrizi, which targets several immunology conditions. Skyrizi's sales have been growing at an incredibly rapid rate. Together with Rinvoq, AbbVie's immunology lineup has successfully filled the gap left by Humira. That's an important reason to consider the stock: AbbVie's ability to overcome a significant patent cliff speaks volumes about its innovative abilities. Beyond that, AbbVie's lineup is deep. It features older products that continue to make meaningful contributions to its financial results, such as its Botox franchise, and newer products that can help drive top-line growth for a while, like migraine treatment Qulipta. AbbVie's pipeline also looks deep. The company should be able to record consistent clinical and regulatory wins. Lastly, we can't mention AbbVie without pointing out its incredible dividend track record. The company is part of the exclusive group of Dividend Kings, boasting an active streak of 53 consecutive payout increases, which includes the time it spent as a division of its former parent company, Abbott Laboratories. AbbVie's forward yield of 3.5% is much higher than the S&P 500 's average of 1.3%, and its cash payout ratio looks reasonable at 61.8%. In addition to an excellent underlying business, a strong lineup, and a solid pipeline, AbbVie is an outstanding stock for income-seeking investors. Investing in this company could yield superior returns over the long term. Eli Lilly is a top growth stock to own for years David Jagielski (Eli Lilly): A stock that looks unstoppable right now is Eli Lilly. While many investors will focus on its highly successful GLP-1 drugs, Zepbound and Mounjaro, as the main reasons to invest in the business, there's much more behind the company, and why it's a top growth stock. Eli Lilly has a promising Alzheimer's treatment, Kisunla, which regulators approved for use last year. It's still in the early innings of its growth and according to analysts, it could generate up to $5 billion in annual revenue at its peak. Meanwhile, Eli Lilly is still focusing on developing more life-changing treatments for patients. It's planning to invest $4.5 billion into a research and manufacturing facility, which it calls Lilly Medicine Foundry. By utilizing new manufacturing methods to ensure high efficiency, the new center can help the company scale and bring new products to market faster. The company also has vast resources at its disposal, which can help it invest in research and development and potentially acquire promising businesses along the way. In the trailing 12 months, Eli Lilly has generated $11.1 billion in profit on sales totaling $49 billion. The company's terrific margins, strong growth prospects, and commitment to producing new treatments are why this pharmaceutical stock can be among the best investments you can put in your portfolio right now. A big biotech innovator that's targeting new markets Keith Speights (Vertex Pharmaceuticals): To truly be unstoppable, a company can't have competition that could, well, stop it. Vertex Pharmaceuticals has this covered with its cystic fibrosis (CF) franchise. No other drugmaker has approved therapies that treat the underlying cause of CF. The number of companies with experimental CF therapies in late-stage clinical testing that could compete with Vertex totals... zero. Actually, Vertex's biggest rival in treating CF is itself. The company's newest CF therapy, Alyftrek, offers a more convenient once-per-day dosing than its current top-seller, Kaftrio/Trikafta. However, CF isn't the main reason why I like Vertex. My primary interests lie with other indications the biotech innovator is targeting. For example, Vertex won U.S. regulatory approval for Journavx earlier this year. It's the first new class of pain medication in over 20 years. Journavx is safe and effective, with none of the side effects and addictive potential associated with opioids -- because it isn't an opioid. The company's pipeline features promising late-stage programs that could further expand Vertex's market opportunity. Inaxaplin targets APOL1-mediated kidney disease, which affects around 250,000 patients worldwide. Povetacicept holds the potential to treat multiple kidney diseases, with IgA nephropathy first on the list with a patient population of over 1 million. Zimislecel could cure severe type 1 diabetes. At first glance, Vertex might seem to be priced at a premium, with its shares trading at 26.3 times forward earnings. However, the company's growth prospects are so strong that its valuation is attractive. Vertex's price-to-earnings-to-growth (PEG) ratio, based on analysts' five-year earnings growth estimates, is a super-low 0.58. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in AbbVie and Vertex Pharmaceuticals. Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Tyler Technologies (TYL) Receives a Rating Update from a Top Analyst
Tyler Technologies (TYL) Receives a Rating Update from a Top Analyst

Globe and Mail

time35 minutes ago

  • Globe and Mail

Tyler Technologies (TYL) Receives a Rating Update from a Top Analyst

In a report released today, Trevor J. Walsh from Citizens JMP reiterated a Buy rating on Tyler Technologies, with a price target of $700.00. The company's shares closed yesterday at $584.56. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. J. Walsh covers the Technology sector, focusing on stocks such as Zscaler, CyberArk Software, and Cloudflare. According to TipRanks, J. Walsh has an average return of 31.3% and a 73.23% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tyler Technologies with a $672.56 average price target, representing a 15.05% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $708.00 price target. TYL market cap is currently $25.29B and has a P/E ratio of 83.59. Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TYL in relation to earlier this year. Most recently, in June 2025, Brian K. Miller, the EVP & CFO of TYL sold 1,200.00 shares for a total of $696,857.01.

nVent (NVT) Q2 EPS Up 28 Revenue Up 30
nVent (NVT) Q2 EPS Up 28 Revenue Up 30

Globe and Mail

time36 minutes ago

  • Globe and Mail

nVent (NVT) Q2 EPS Up 28 Revenue Up 30

Key Points Adjusted EPS surged 28% to $0.86, topping the $0.79 analyst estimate (non-GAAP) and exceeding expectations by 8.9% on a non-GAAP basis. Revenue (GAAP) climbed 30% to $963 million, beating consensus by 6.0% (GAAP revenue) and reflecting both organic and acquisition-driven growth. Operating margins and free cash flow declined from the prior year, primarily due to acquisition mix and tariff costs. These 10 stocks could mint the next wave of millionaires › nVent Electric Plc (NYSE:NVT), a global provider of electrical connection and protection solutions for infrastructure and industrial markets, published its second quarter 2025 earnings on August 1, 2025. The headline news was a significant beat on both adjusted earnings per share (EPS) (non-GAAP) and revenue (GAAP). Adjusted EPS reached $0.86, up 28% (non-GAAP), outperforming the $0.79 consensus forecast for adjusted EPS (non-GAAP). Reported revenue grew to $963 million (GAAP), outpacing the $908.38 million GAAP estimate and up 30% year-over-year. Most of this growth was driven by large acquisitions in power utilities and data centers, as well as robust product launches. Despite this, both reported and adjusted operating margins (return on sales) and free cash flow (non-GAAP) declined year-over-year. Overall, the quarter demonstrated nVent's ability to deliver on its growth strategy, but also surfaced challenges in margin management and cash flow. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About nVent Electric Plc and Its Strategy nVent Electric Plc designs and manufactures products that connect and protect electrical systems. Its portfolio includes enclosures, electrical connections, and engineered solutions that serve industries such as data centers, utilities, renewables, and industrial automation. The business supports the growing need for safe and reliable power across global infrastructure. The company's current strategy focuses on acquiring businesses that expand its reach in the rapidly growing sectors of electrical infrastructure, data centers, and renewable energy. nVent has made several large acquisitions, including ECM Industries and Trachte, to bolster these offerings. Key to success are continued innovation, reliable supply chain channels, and operational efficiency using lean principles. A strong culture of employee engagement also supports its long-term strategic aims. Quarter Highlights: Financial and Operational Drivers The second quarter featured standout headline growth, with reported revenue up 30%. Organic sales growth, which strips out the effects of acquired businesses and currency, was 9%. Acquisitions contributed 20.7 percentage points to the reported growth, while currency effects were negligible. This growth strategy has intentionally shifted nVent's business mix toward longer-cycle, high-growth infrastructure domains. As a result, power utilities and data centers now make up an estimated 40% of overall company sales. Earnings (non-GAAP) also exceeded expectations. Adjusted EPS climbed to $0.86, an 8.9% beat over consensus and a 28% year-over-year increase. Adjusted operating income also rose by 18%. These gains were supported by strong performances in newly acquired product families like control buildings, bus systems, and switchgear. These are essential systems for managing power distribution and supporting growth in sectors like data centers, power utilities, and renewables. Across product lines, the business launched 35 new offerings in Q1, aiding both organic growth and the company's push into sustainable, electrification-focused markets. While sales momentum was clear, profitability faced pressure. Both operating margin (GAAP) and adjusted return on sales (non-GAAP) dropped from a year earlier -- the adjusted return on sales margin (non-GAAP) fell to 20.8% from 22.9%. This reduction was attributed to margin dilution from acquisitions, additional costs from tariffs, and investments to support second-half growth. The impact was seen across both major segments. Systems Protection's adjusted return on sales reached 21.7%, down 1.8 percentage points, while Electrical Connections adjusted return on sales fell to 28.7%, down 2.2 percentage points year-over-year. Free cash flow (non-GAAP) was $74 million, declining from $100.6 million in Q2 2024. However, the company continued balanced capital allocation, including $253.1 million in share repurchases year-to-date as of Q1 and a dividend of $0.20 per share, which was a 5% increase from the prior year. Business and Product Developments Strategic acquisitions remained central to nVent's expansion this quarter. The integration of Trachte -- a provider of control building systems -- and Avail EPG enhanced nVent's capabilities in high-growth sectors like utilities and data centers. According to management, both acquisitions performed better than expected and contributed to growth synergies. A direct quote from leadership noted: 'The Trachte and Electrical Products Group acquisitions performed better than expected, further strengthening our position in the high growth infrastructure vertical, including power utilities, data centers and renewables.' Product innovation was another highlight. The company introduced 35 new products in the quarter, helping drive double-digit growth in orders and backlog in Q1. Many solutions were designed to meet the growing global demand for electrification, sustainability, and digital transformation. The business emphasized opportunities in data centers, renewables, and electrical grid expansion, with new products tailored for improved energy efficiency and resiliency. These launches complemented nVent's existing portfolio of enclosures and electrical connectors, keeping it aligned with the latest industry trends. The business relies on an extensive distribution network. Over 60% of nVent's revenue now flows through distribution partners, providing broad market access. Management reported strong double-digit order growth, particularly in infrastructure segments for Q1. Growing backlog -- now more than a four-fold increase -- has given the company good visibility for the rest of the year. Operational efficiency is a key part of nVent's culture, with lean manufacturing practices dating back decades. The company called out the doubling of control building output at Trachte as the result of lean improvements. Management also noted that investments and costs related to tariffs weighed on profit margins, but it expects these to be offset over time through pricing, productivity, and integration benefits as new acquisitions are fully absorbed into operations. Looking Ahead: Guidance and Focus Areas nVent raised its full-year 2025 guidance based on strong results and order momentum. Management now expects reported sales growth of 24–26% and organic sales growth of 8–10%. The adjusted EPS (non-GAAP) range was also lifted to $3.22–$3.30, from $3.03–$3.13 previously. For Q3, the business projects reported sales growth of 27–29%, organic growth of 11–13%, and adjusted EPS between $0.86 and $0.88. The company cited its expanded backlog, double-digit order growth, and robust demand in its core infrastructure markets as reasons for its more optimistic full-year outlook. Investors should keep an eye on several areas in the coming quarters. Management has highlighted a $120 million tariff headwind, with plans to offset these costs through pricing, productivity, and supply chain actions. Margin recovery is a top priority, with expectations that synergy capture and pricing actions will improve profitability in the second half of the year. Additionally, trends toward electrification and digital infrastructure are likely to sustain demand for nVent's solutions in years ahead. The quarterly dividend was raised 5% to $0.20 per share, payable in Q3. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 29, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store